Madhu Kumar

3 Stocks To Double Down On In 2022
How Close Are Biotechs To Bringing A COVID-19 Treatment To Market?
Baird: Preclinical Data Inspires 'Early Optimism' In Lead Intellia Therapeutics Asset
How Close Are Biotechs To Bringing A COVID-19 Treatment To Market?
Baird: Preclinical Data Inspires 'Early Optimism' In Lead Intellia Therapeutics Asset
Recent Assembly Biosciences Weakness Provides Attractive Entry Point, B Riley FBR Says In Upgrade
Analysts React To Arrowhead's Janssen Collaboration: Downside In Stock May Be 'Misguided'

Madhu Kumar Recent News

Deciphera Pharma Hit With Sell-Side Downgrade On Valuation After 50% Gain
B Riley Likes Tocagen On Prospects For Company's Brain Cancer Drug
With Alnylam Pharma Down More Than 15%, Analyst Says Buy The Dip
Analyst: Clementia Has Potential To Reach Unmet Market For Rare Bone Disease
Dicerna Pharma Has Multiple Pipeline Opportunities, Tough Competition, Analyst Says In Neutral Initiation
Priority Review For Tetraphase's Eravacycline A 'Key Positive,' Analyst Says
Deciphera Pharma Scores A Sell-Side Recommendation
Alnylam Pharma The New 'Alpha Generator' Stock Pick At FBR
Why Ionis Results Today Support A Pair Trade With Alnylam
Chardan Still Skeptical Of Coversin, Reiterates Sell Rating On Akari Therapeutics
Clovis Shares Reiterated As A Sell Following 10% Rally
Reasons To Stay Bullish On Alnylam In The New Year
For Arbutus' Hepatitis B Treatment, 'Liver Safety Risk Overwhelms Promising Efficacy'
Alnylam Is Now The Leader In The Clinical HBV RNAi Therapy Space
Arrowhead Pharma Downgraded Following EX-1 RNAi Program Discontinuations
Chardan Recommends Selling Clovis Oncology
Achillion Pharma Initiated At Sell By Chardan, Sees ≥60% Downside
Chardan Analysts Initiate Coverage On Akari Therapeutics With A Sell Rating
ProQR Therapeutics Has Limited Downside Or Upside According to Chardan
Arbutus Biopharma Taken Off Of Chardan's Sell List
Regulus RG-101 Results 'Potentially Breakthrough,' Chardan Says; Target Raised To $20
5 Reasons Arrowhead Pharma Is A Hepatitis B Leader
Analyst Highlights Regulus Therapeutics' 'Disruptive 2016 Catalysts'